IMUNON Granted Continued Listing Extension by Nasdaq to Complete Compliance Plan
IMUNON (NASDAQ: IMNN), a clinical-stage company developing DNA-mediated immunotherapy in Phase 3, has received an extension from the Nasdaq Hearing Panel to maintain its stock market listing.
The Panel has granted IMUNON's request for an exception after reviewing the company's compliance strategies. The company has already achieved compliance with the Equity Rule through recent fundraising activities and must now focus on meeting the minimum shareholder equity requirement and minimum bid price requirement within the approved timeframe.
CEO Stacy Lindborg expressed confidence in executing the compliance plan to maintain Nasdaq listing and deliver long-term shareholder value.
IMUNON (NASDAQ: IMNN), un'azienda in fase clinica che sviluppa immunoterapia mediata da DNA in fase 3, ha ottenuto una proroga dal Nasdaq Hearing Panel per mantenere la quotazione in borsa.
Il Panel ha accolto la richiesta di eccezione di IMUNON dopo aver esaminato le strategie di conformità dell'azienda. La società ha già raggiunto la conformità alla Equity Rule tramite recenti attività di raccolta fondi e ora deve concentrarsi sul soddisfare il requisito minimo di patrimonio netto degli azionisti e il requisito minimo di prezzo di offerta entro il termine approvato.
La CEO Stacy Lindborg ha espresso fiducia nell'esecuzione del piano di conformità per mantenere la quotazione al Nasdaq e garantire valore a lungo termine per gli azionisti.
IMUNON (NASDAQ: IMNN), una empresa en fase clínica que desarrolla inmunoterapia mediada por ADN en Fase 3, ha recibido una extensión del Nasdaq Hearing Panel para mantener su cotización en bolsa.
El Panel ha concedido la solicitud de excepción de IMUNON tras revisar las estrategias de cumplimiento de la compañía. La empresa ya ha logrado cumplir con la Equity Rule mediante recientes actividades de recaudación de fondos y ahora debe enfocarse en cumplir con el requisito mínimo de patrimonio neto de los accionistas y el requisito mínimo de precio de oferta dentro del plazo aprobado.
La CEO Stacy Lindborg expresó confianza en la ejecución del plan de cumplimiento para mantener la cotización en Nasdaq y generar valor a largo plazo para los accionistas.
IMUNON (NASDAQ: IMNN)은 3상 단계의 DNA 매개 면역치료제를 개발하는 임상 단계 기업으로, 나스닥 청문 패널로부터 주식시장 상장 유지를 위한 연장 승인을 받았습니다.
패널은 회사의 준수 전략을 검토한 후 IMUNON의 예외 요청을 승인했습니다. 회사는 최근 자금 조달 활동을 통해 Equity Rule을 이미 준수하였으며, 이제 승인된 기간 내에 최소 주주 자본 요건과 최소 입찰 가격 요건을 충족하는 데 집중해야 합니다.
CEO Stacy Lindborg는 나스닥 상장 유지와 장기 주주 가치를 제공하기 위한 준수 계획 실행에 자신감을 표명했습니다.
IMUNON (NASDAQ : IMNN), une entreprise en phase clinique développant une immunothérapie médiée par l'ADN en phase 3, a obtenu une prolongation du Nasdaq Hearing Panel pour maintenir sa cotation en bourse.
Le Panel a accordé la demande d'exception d'IMUNON après avoir examiné les stratégies de conformité de la société. L'entreprise a déjà atteint la conformité avec la règle Equity grâce à des levées de fonds récentes et doit désormais se concentrer sur le respect des exigences minimales de capitaux propres des actionnaires et du prix d'offre minimum dans le délai approuvé.
La PDG Stacy Lindborg a exprimé sa confiance dans l'exécution du plan de conformité pour maintenir la cotation Nasdaq et offrir une valeur à long terme aux actionnaires.
IMUNON (NASDAQ: IMNN), ein klinisch fortgeschrittenes Unternehmen, das eine DNA-vermittelte Immuntherapie in Phase 3 entwickelt, hat von dem Nasdaq Hearing Panel eine Verlängerung erhalten, um seine Börsennotierung aufrechtzuerhalten.
Das Panel hat IMUNONs Antrag auf eine Ausnahme genehmigt, nachdem es die Compliance-Strategien des Unternehmens geprüft hatte. Das Unternehmen hat bereits durch kürzliche Kapitalbeschaffungsmaßnahmen die Einhaltung der Equity Rule erreicht und muss sich nun darauf konzentrieren, die Mindestanforderung an das Aktionärskapital und die Mindestgebotspreisanforderung innerhalb des genehmigten Zeitrahmens zu erfüllen.
CEO Stacy Lindborg zeigte sich zuversichtlich, den Compliance-Plan umzusetzen, um die Nasdaq-Notierung zu erhalten und langfristigen Wert für die Aktionäre zu schaffen.
- Already achieved compliance with Nasdaq Equity Rule through recent fundraising
- Received Nasdaq extension to complete compliance plan
- Company has Phase 3 clinical-stage asset in development
- Company currently fails to meet Nasdaq minimum bid price requirement
- May need additional time beyond current extension to achieve full compliance
- Risk of potential delisting if compliance requirements are not met
Management provides Nasdaq Hearing Panel with a comprehensive executable plan for long term compliance
LAWRENCEVILLE, N.J., July 15, 2025 (GLOBE NEWSWIRE) -- IMUNON, Inc. (Nasdaq: IMNN), a clinical-stage company in Phase 3 development of its DNA-mediated immunotherapy, today announced that the Nasdaq Hearing Panel has granted its request for an exception to complete its compliance plan, allowing the Company to maintain its listing on the Nasdaq Stock Market.
Following a comprehensive review of IMUNON’s strategies to regain compliance, the Nasdaq Hearing Panel stated that IMUNON has already achieved compliance with the Equity Rule through recent fundraising activities. To ensure sustained compliance with the minimum shareholder equity requirement and to regain compliance with the minimum bid price requirement, the Company will implement the compliance plan recently presented to the Hearing Panel.
The Panel has approved an exception tailored to the time needed for IMUNON to regain compliance, rather than the full 180-day period initially requested. The Company is committed to meeting these requirements within the designated timeframe. Should additional time be necessary, IMUNON may submit a request for an extension to the Panel.
“We are pleased with the Nasdaq Hearing Panel’s decision, which reflects confidence in our straightforward and executable compliance plan,” said Stacy Lindborg, Ph.D., President and CEO of IMUNON. “Our management is fully dedicated to implementing our well thought out plan and taking the necessary steps to maintain our Nasdaq listing. I have every confidence our actions will continue to provide a platform that will deliver long-term value to our shareholders.”
About IMUNON
IMUNON is a clinical-stage biotechnology company focused on advancing a portfolio of innovative treatments that harness the body’s natural mechanisms to generate safe, effective and durable responses across a broad array of human diseases, constituting a differentiating approach from conventional therapies. IMUNON is developing its non-viral DNA technology across its modalities. The first modality, TheraPlas®, is developed for the gene-based delivery of cytokines and other therapeutic proteins in the treatment of solid tumors where an immunological approach is deemed promising. The second modality, PlaCCine®, is developed for the gene delivery of viral antigens that can elicit a strong immunological response.
The Company’s lead clinical program, IMNN-001, is a DNA-based immunotherapy for the localized treatment of advanced ovarian cancer that has completed multiple clinical trials including one Phase 2 clinical trial (OVATION 2). IMNN-001 works by instructing the body to produce safe and durable levels of powerful cancer-fighting molecules, such as interleukin-12 and interferon gamma, at the tumor site. Additionally, the Company has completed dosing in a first-in-human study of its COVID-19 booster vaccine (IMNN-101). The Company will continue to leverage these modalities and to advance, either directly or through partnership, the technological frontier of plasmid DNA to better serve patients with difficult-to-treat conditions. For more information, please visit www.imunon.com.
Forward-Looking Statements
IMUNON wishes to inform readers that forward-looking statements in this news release are made pursuant to the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical fact, including, but not limited to, statements regarding the Company’s ability to regain compliance with Nasdaq’s continued listing requirements, the timing of enrollment of the Company’s clinical trials, the potential of any therapies developed by the Company to fulfill unmet medical needs, the market potential for the Company’s products, if approved, the potential efficacy and safety profile of our product candidates, and the Company’s plans and expectations with respect to its development programs more generally, are forward-looking statements. We generally identify forward-looking statements by using words such as “may,” “will,” “expect,” “plan,” “anticipate,” “estimate,” “intend” and similar expressions (as well as other words or expressions referencing future events, conditions or circumstances), and include statements regarding our planned stock split. Readers are cautioned that such forward-looking statements involve risks and uncertainties including, without limitation, risks and uncertainties related to the reverse stock split having the desired effect, our ability to regain compliance with Nasdaq’s listing requirements, the potential de-listing of our shares on Nasdaq, risks and uncertainties relating to unforeseen changes in the course of research and development activities and in clinical trials, including the fact that interim results are not necessarily indicative of final results; the uncertainties of and difficulties in analyzing interim clinical data; the significant expense, time and risk of failure in conducting clinical trials; the need for IMUNON to evaluate its future development plans; possible actions by customers, suppliers, competitors or regulatory authorities; and other risks detailed from time to time in IMUNON’s filings with the Securities and Exchange Commission. IMUNON assumes no obligation, except to the extent required by law, to update or supplement forward-looking statements that become untrue because of subsequent events, new information or otherwise.
Contacts:
| Media | Investors |
| Jenna Urban | Peter Vozzo |
| CG Life | ICR Healthcare |
| 212-253-8881 | 443-213-0505 |
| jurban@cglife.com | peter.vozzo@icrhealthcare.com |
FAQ
What did Nasdaq grant to IMUNON (IMNN) on July 15, 2025?
What requirements does IMUNON (IMNN) need to meet for Nasdaq compliance?
Has IMUNON (IMNN) met any of the Nasdaq compliance requirements?
What happens if IMUNON (IMNN) needs more time for Nasdaq compliance?
What stage is IMUNON's (IMNN) main product development?
